Literature DB >> 25599740

Successful treatment of calciphylaxis with pamidronate.

Nakysa Hooman1, Rama Naghshi-Zadiyan, Mitra Mehrazma, Fariba Jahangiri.   

Abstract

Calciphylaxis is a complication of chronic kidney disease characterized by necrotic lesion in the skin. Histological examination reveals microcalcification of medium-sized blood vessels. We report on a 21-month-old girl with end-stage renal disease with severe calcium-phosphate imbalance. Calciphylaxis process started when she received calcium gluconate intravenously the day before the surgery to correct hypocalcemia and continued progressively despite peritoneal dialysis and forced stopping calcium-containing medication. Pamidronate, 0.5 mg/kg/d, was administered for 6 days and then once a week for 5 weeks. After 1 week, the skin lesion started to heal and circulation improved, and after 6 weeks, all skin lesions completely recovered. Pamidronate was effective to stop calciphylaxis in this case with advanced renal insufficiency and severe calcium-phosphate imbalance. Medical or surgical debridement are not suggested and lesions might recover without scar by pamidronate.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25599740

Source DB:  PubMed          Journal:  Iran J Kidney Dis        ISSN: 1735-8582            Impact factor:   0.892


  3 in total

1.  Rare etiology of severe calf pain and induration in a child with end-stage renal disease: Answers.

Authors:  Gurinder Kumar; Mohammed Khair AlGhabra; Aman Sohal; Baker Ayyash; Nitin Airon; Eihab AlKhasawneh
Journal:  Pediatr Nephrol       Date:  2017-05-04       Impact factor: 3.714

2.  Diagnosis and treatment of calciphylaxis in patients with chronic kidney disease.

Authors:  Leandro Junior Lucca; Rosa Maria Affonso Moysés; Adriano Souza Lima Neto
Journal:  J Bras Nefrol       Date:  2021-12-03

3.  Gastrointestinal Bleeding Secondary to Calciphylaxis.

Authors:  Nancy Gupta; Khwaja F Haq; Sugandhi Mahajan; Prashant Nagpal; Bijal Doshi
Journal:  Am J Case Rep       Date:  2015-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.